Sage Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sage Therapeutics, Inc. (SAGE) is a biopharmaceutical company committed to pioneering solutions to deliver life-changing brain health medicines targeting central nervous system disorders. The company discovers, develops, and commercializes treatments focused on postpartum depression and other brain health conditions through selective allosteric modulation of synaptic and extrasynaptic GABA and NMDA receptors; its commercially available products include ZURZUVAE (zuranolone), the first FDA-approved oral therapy for postpartum depression in adults; and ZULRESSO (brexanolone), an intravenous formulation for the same indication. Its pipeline encompasses clinical-stage candidates such as SAGE-324 for essential tremor and other GABA hypofunction disorders, along with earlier-stage programs for major depressive disorder, bipolar depression, Parkinson's disease, insomnia, and epileptiform disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage operates primarily in the United States with subsidiaries in Europe including the United Kingdom, Germany, Switzerland, Scotland, England, and Wales. In June 2025, Sage entered a definitive agreement to be acquired by Supernus Pharmaceuticals in a transaction valued at up to $795 million, including $561 million in cash at $8.5 per share plus a contingent value right of up to $3.5 per share tied to commercial milestones for ZURZUVAE; the deal, which received unanimous board approval, is expected to close in the third quarter of 2025, subject to regulatory approvals, adding ZURZUVAE to Supernus' CNS portfolio alongside products like Qelbree, ONAPGO, and GOCOVRI while generating up to $200 million in annual cost synergies. Earlier, in September 2024, Biogen terminated its option on the SAGE-324 program, effective February 2025, following prior challenges including a 2024 restructuring with layoffs of 33% of its workforce to support ZURZUVAE commercialization amid collaboration revenues of $36.1 million in 2024 and $23.2 million in Q2 2025.
Sage Potash Announces Single Derrick Drill Rig Mobilization and Site Preparation at Sage Plain Potash Project in Utah
Sage Potash Secures All Permits for its Drilling Program at Sage Plain Potash Project in Utah
Rubrik Launches Rubrik Agent Cloud for Anthropic's Claude Code
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)
What Makes Sage Therapeutics (SAGE) a New Buy Stock
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders
Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation